Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients

Yoonjung Kim, Mee Yon Cho, Juwon Kim, Sung Nam Kim, Seoung Chul Oh, Kyung A. Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recently, the Cancer Genome Atlas (TCGA) Research Network and Asian Cancer Research Group provided a new classification of gastric cancer (GC) to aid the development of biomarkers for targeted therapy and predict prognosis. We studied associations between genetically aberrant profiles of cancer-related genes, environmental factors, and histopathological features in 107 paired gastric tumornon- tumor tissue GC samples. 6.5% of our GC cases were classified as the EBV subtype, 17.8% as the MSI subtype, 43.0% as the CIN subtype, and 32.7% as the GS subtype. The distribution of four GC subgroups based on the TCGA and our dataset were similar. The MSI subtype showed a hyper-mutated status and the best prognosis among molecular subtype. However, molecular classification based on the four GC subtypes showed no significant survival differences in terms of overall survival (p= 0.548) or relapse-free survival (RFS, p=0.518). The P619fs*43 in ZBTB20 was limited to MSI group (n= 5/19, 26.3%), showing similar trends observed in TCGA dataset. Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were detected in 34.6% of GC cases (37 individual cases). We also found two cases with likely pathogenic variants (NM_004360.4: c. 2494 G > A, p.V832M) in the CDH1 gene. Here, we classified molecular subtypes of GC according to the TCGA system and provide a critical starting point for the design of more appropriate clinical trials based on a comprehensive analysis of genetic alterations in Korean GC patients.

Original languageEnglish
Pages (from-to)69888-69905
Number of pages18
JournalOncotarget
Volume8
Issue number41
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Stomach Neoplasms
Molecular Biology
Atlases
Neoplasms
Genome
Survival
Neoplasm Genes
Human Herpesvirus 4
Phosphatidylinositol 3-Kinases
Research
Stomach
Biomarkers
Clinical Trials
Recurrence
Genes
N-methylsuccinimide

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Yoonjung ; Cho, Mee Yon ; Kim, Juwon ; Kim, Sung Nam ; Oh, Seoung Chul ; Lee, Kyung A. / Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. In: Oncotarget. 2017 ; Vol. 8, No. 41. pp. 69888-69905.
@article{c8407bf843664d4783ff9eb47ba1d88c,
title = "Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients",
abstract = "Recently, the Cancer Genome Atlas (TCGA) Research Network and Asian Cancer Research Group provided a new classification of gastric cancer (GC) to aid the development of biomarkers for targeted therapy and predict prognosis. We studied associations between genetically aberrant profiles of cancer-related genes, environmental factors, and histopathological features in 107 paired gastric tumornon- tumor tissue GC samples. 6.5{\%} of our GC cases were classified as the EBV subtype, 17.8{\%} as the MSI subtype, 43.0{\%} as the CIN subtype, and 32.7{\%} as the GS subtype. The distribution of four GC subgroups based on the TCGA and our dataset were similar. The MSI subtype showed a hyper-mutated status and the best prognosis among molecular subtype. However, molecular classification based on the four GC subtypes showed no significant survival differences in terms of overall survival (p= 0.548) or relapse-free survival (RFS, p=0.518). The P619fs*43 in ZBTB20 was limited to MSI group (n= 5/19, 26.3{\%}), showing similar trends observed in TCGA dataset. Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were detected in 34.6{\%} of GC cases (37 individual cases). We also found two cases with likely pathogenic variants (NM_004360.4: c. 2494 G > A, p.V832M) in the CDH1 gene. Here, we classified molecular subtypes of GC according to the TCGA system and provide a critical starting point for the design of more appropriate clinical trials based on a comprehensive analysis of genetic alterations in Korean GC patients.",
author = "Yoonjung Kim and Cho, {Mee Yon} and Juwon Kim and Kim, {Sung Nam} and Oh, {Seoung Chul} and Lee, {Kyung A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19435",
language = "English",
volume = "8",
pages = "69888--69905",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. / Kim, Yoonjung; Cho, Mee Yon; Kim, Juwon; Kim, Sung Nam; Oh, Seoung Chul; Lee, Kyung A.

In: Oncotarget, Vol. 8, No. 41, 01.01.2017, p. 69888-69905.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients

AU - Kim, Yoonjung

AU - Cho, Mee Yon

AU - Kim, Juwon

AU - Kim, Sung Nam

AU - Oh, Seoung Chul

AU - Lee, Kyung A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Recently, the Cancer Genome Atlas (TCGA) Research Network and Asian Cancer Research Group provided a new classification of gastric cancer (GC) to aid the development of biomarkers for targeted therapy and predict prognosis. We studied associations between genetically aberrant profiles of cancer-related genes, environmental factors, and histopathological features in 107 paired gastric tumornon- tumor tissue GC samples. 6.5% of our GC cases were classified as the EBV subtype, 17.8% as the MSI subtype, 43.0% as the CIN subtype, and 32.7% as the GS subtype. The distribution of four GC subgroups based on the TCGA and our dataset were similar. The MSI subtype showed a hyper-mutated status and the best prognosis among molecular subtype. However, molecular classification based on the four GC subtypes showed no significant survival differences in terms of overall survival (p= 0.548) or relapse-free survival (RFS, p=0.518). The P619fs*43 in ZBTB20 was limited to MSI group (n= 5/19, 26.3%), showing similar trends observed in TCGA dataset. Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were detected in 34.6% of GC cases (37 individual cases). We also found two cases with likely pathogenic variants (NM_004360.4: c. 2494 G > A, p.V832M) in the CDH1 gene. Here, we classified molecular subtypes of GC according to the TCGA system and provide a critical starting point for the design of more appropriate clinical trials based on a comprehensive analysis of genetic alterations in Korean GC patients.

AB - Recently, the Cancer Genome Atlas (TCGA) Research Network and Asian Cancer Research Group provided a new classification of gastric cancer (GC) to aid the development of biomarkers for targeted therapy and predict prognosis. We studied associations between genetically aberrant profiles of cancer-related genes, environmental factors, and histopathological features in 107 paired gastric tumornon- tumor tissue GC samples. 6.5% of our GC cases were classified as the EBV subtype, 17.8% as the MSI subtype, 43.0% as the CIN subtype, and 32.7% as the GS subtype. The distribution of four GC subgroups based on the TCGA and our dataset were similar. The MSI subtype showed a hyper-mutated status and the best prognosis among molecular subtype. However, molecular classification based on the four GC subtypes showed no significant survival differences in terms of overall survival (p= 0.548) or relapse-free survival (RFS, p=0.518). The P619fs*43 in ZBTB20 was limited to MSI group (n= 5/19, 26.3%), showing similar trends observed in TCGA dataset. Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were detected in 34.6% of GC cases (37 individual cases). We also found two cases with likely pathogenic variants (NM_004360.4: c. 2494 G > A, p.V832M) in the CDH1 gene. Here, we classified molecular subtypes of GC according to the TCGA system and provide a critical starting point for the design of more appropriate clinical trials based on a comprehensive analysis of genetic alterations in Korean GC patients.

UR - http://www.scopus.com/inward/record.url?scp=85030223751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030223751&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19435

DO - 10.18632/oncotarget.19435

M3 - Article

AN - SCOPUS:85030223751

VL - 8

SP - 69888

EP - 69905

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -